Are stem cells available for retail purchase like other pharmaceuticals?

Currently, the use of Mesenchymal Stem Cells (MSCs) for treating various diseases has been approved in a number of countries, although the specific approval processes and indications vary widely. The question patients ask most often, can I just buy a course of MSCs the way I buy a course of antibiotics, has a structural answer rooted in what stem cells actually are.

Where MSCs are currently approved

Graft-versus-host disease following bone marrow transplantation, approved for MSC treatment in Canada and Japan. Crohn's disease, approved for MSC treatment in European countries. Buerger's disease, approved for MSC treatment in India. Spinal cord injuries, approved for MSC treatment in Japan. ALS and osteoarthritis, approved for MSC treatment in South Korea.

Each of these approvals took years of trial work, regulatory dialogue and post-marketing follow-up. The orthopaedic signal that supported the Korean OA approval is part of the literature we cover in MSCs and osteoarthritis, reading the trial data, if you want the clinical detail.

Why they can't be packaged and sold off the shelf

The research required for drug registration is extremely costly. New drugs often require billions of dollars in investment, making research to support the registration of stem cell therapies increasingly difficult, particularly for autologous products, where each dose is patient-specific by definition.

More fundamentally: stem cells are living cells. They cannot be packaged and sold like ordinary drugs. Mesenchymal stem cells, in particular, require several weeks of culturing to reach therapeutic quantities. They must undergo rigorous testing to ensure they are free of contamination and safe for use. They are often stored frozen in liquid nitrogen until needed and have a limited lifespan once thawed.

Any product that does not meet these criteria cannot be considered a living cell or a mesenchymal stem cell. Anything sold as such is, at best, a misrepresentation of biology, and at worst, a regulatory and safety risk. This is part of why our stem-cell technology programme is structured as an end-to-end clinical service rather than a product sold by the vial.

What 'approved' means in practice

An approval in one country does not transfer automatically to another. Each regulator, TFDA in Thailand, PMDA in Japan, EMA in the EU, FDA in the US, sets its own standard for what evidence is required, what indications are permitted, and what the post-marketing surveillance looks like. Off-label use is sometimes legal and sometimes not, depending on jurisdiction and indication.

We treat this seriously. The list of indications we offer at the clinic maps to the evidence base and the regulatory framework that governs us. The longer read on that framework, what changed in Thailand specifically in 2025, is covered in Thailand's regenerative medicine framework, what changed in 2025.

Why we frame this as a feature

The thing that makes stem-cell therapy impossible to package and ship is the same thing that makes it work: living cells with identity, characterisation, and a continuous quality chain. Take that away and you no longer have a stem-cell therapy, you have a vial of something that was once a stem-cell therapy. The constraint defines the practice.

The deeper read on why this chain of custody is load-bearing is in autologous vs allogeneic, why our chain of custody matters. The certifications that prove a clinic is actually running that chain are covered in ISCT, PIC/S, ISO 15189, what the certifications actually mean.